Final data from CombiGene’s preclinical proof-of-concept-study (the long-term study) show that CombiGene’s candidate drug, CG01, has clear antiepileptic effects. The study has demonstrated that CG01 reduces the frequency and duration of epileptic seizures in treatment-responsive animals. A couple of the animals were completely free of seizures after being treated. No side effects have been observed in the study.
The study, which began in April 2017, has been conducted at Lund University under the direction of Professor Merab Kokaia, one of CombiGene’s scientific founders and head of the Epilepsy Centre at Lund University’s Faculty of Medicine. The principal aim of the study is to provide additional evidence of the antiepileptic effect of CombiGene’s candidate drug.